
Calidi Biotherapeutics is set to host a live investor webinar on April 24, 2025, showcasing its advanced cancer immunotherapy pipeline. The event, scheduled for 4:15 p.m. ET, will feature the company’s new Chief Medical Officer, Dr. Guy Travis Clifton, who will provide comprehensive insights into the organization’s innovative stem cell-based delivery platforms.
The webinar will spotlight several key therapeutic candidates, including the FDA-cleared CLD-201, which is progressing toward clinical trials for solid tumors. Additionally, the presentation will offer program updates on CLD-400, targeting metastatic and lung cancer, and CLD-101, focused on high-grade gliomas.
Calidi’s proprietary technology represents a significant advancement in cancer treatment, utilizing potent allogeneic stem cells capable of carrying oncolytic viruses. These innovative platforms are designed to enhance the immune system’s ability to combat cancer by protecting, amplifying, and potentiating oncolytic viruses, potentially improving both treatment efficacy and patient safety.
The company’s unique approach involves developing preclinical off-the-shelf enveloped virotherapies specifically designed to target disseminated solid tumors. This dual strategy offers the potential to not only treat existing cancers but potentially prevent metastatic disease progression.
Following the presentation, the webinar will include a live question-and-answer session, providing investors and stakeholders an opportunity to gain deeper understanding of Calidi’s groundbreaking research and therapeutic development strategies.

This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRampâ„¢. The source URL for this press release is Calidi Biotherapeutics to Unveil Cancer Immunotherapy Advances in Upcoming Investor Webinar.